These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 15565326

  • 1. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines.
    Duan Z, Lamendola DE, Duan Y, Yusuf RZ, Seiden MV.
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):277-85. PubMed ID: 15565326
    [Abstract] [Full Text] [Related]

  • 2. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line.
    Lamendola DE, Duan Z, Yusuf RZ, Seiden MV.
    Cancer Res; 2003 May 01; 63(9):2200-5. PubMed ID: 12727840
    [Abstract] [Full Text] [Related]

  • 3. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.
    Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV.
    Clin Cancer Res; 1999 Nov 01; 5(11):3445-53. PubMed ID: 10589757
    [Abstract] [Full Text] [Related]

  • 4. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
    Villeneuve DJ, Hembruff SL, Veitch Z, Cecchetto M, Dew WA, Parissenti AM.
    Breast Cancer Res Treat; 2006 Mar 01; 96(1):17-39. PubMed ID: 16322897
    [Abstract] [Full Text] [Related]

  • 5. GBP1 overexpression is associated with a paclitaxel resistance phenotype.
    Duan Z, Foster R, Brakora KA, Yusuf RZ, Seiden MV.
    Cancer Chemother Pharmacol; 2006 Jan 01; 57(1):25-33. PubMed ID: 16028104
    [Abstract] [Full Text] [Related]

  • 6. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
    Goto T, Takano M, Sakamoto M, Kondo A, Hirata J, Kita T, Tsuda H, Tenjin Y, Kikuchi Y.
    Oncol Rep; 2006 May 01; 15(5):1265-71. PubMed ID: 16596196
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC, Liang YC, Klutz A, Hsu CI, Lin CF, Mold DE, Chou TC, Lee YC, Huang RC.
    Cancer Chemother Pharmacol; 2006 Nov 01; 58(5):640-53. PubMed ID: 16544145
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A microarray based expression profiling of paclitaxel and vincristine resistant MCF-7 cells.
    Kars MD, Işeri OD, Gündüz U.
    Eur J Pharmacol; 2011 Apr 25; 657(1-3):4-9. PubMed ID: 21320484
    [Abstract] [Full Text] [Related]

  • 11. RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines.
    Yang C, Hornicek FJ, Wood KB, Schwab JH, Mankin H, Duan Z.
    Cancer Chemother Pharmacol; 2009 Aug 25; 64(3):607-14. PubMed ID: 19125251
    [Abstract] [Full Text] [Related]

  • 12. [The selection of taxol resistance associated genes in ovarian cancer cell line by mRNA DD].
    Cheng G, Tian F, Li Y.
    Zhonghua Yi Xue Za Zhi; 2000 Jul 25; 80(7):541-3. PubMed ID: 11798816
    [Abstract] [Full Text] [Related]

  • 13. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
    George JA, Chen T, Taylor CC.
    Cancer Res; 2005 Nov 15; 65(22):10381-8. PubMed ID: 16288028
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Expression microarray analysis reveals genes associated with in vitro resistance to cisplatin in a cell line model.
    Watson MB, Lind MJ, Smith L, Drew PJ, Cawkwell L.
    Acta Oncol; 2007 Nov 15; 46(5):651-8. PubMed ID: 17562441
    [Abstract] [Full Text] [Related]

  • 16. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
    Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, Ishii N, Yanaihara N, Yamada K, Takikawa O, Kawaguchi R, Isonishi S, Tanaka T, Urashima M.
    Clin Cancer Res; 2005 Aug 15; 11(16):6030-9. PubMed ID: 16115948
    [Abstract] [Full Text] [Related]

  • 17. Role of microRNAs in drug-resistant ovarian cancer cells.
    Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C.
    Gynecol Oncol; 2008 Dec 15; 111(3):478-86. PubMed ID: 18823650
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The antitumor activities of curcumin and of its isoxazole analogue are not affected by multiple gene expression changes in an MDR model of the MCF-7 breast cancer cell line: analysis of the possible molecular basis.
    Poma P, Notarbartolo M, Labbozzetta M, Maurici A, Carina V, Alaimo A, Rizzi M, Simoni D, D'Alessandro N.
    Int J Mol Med; 2007 Sep 15; 20(3):329-35. PubMed ID: 17671737
    [Abstract] [Full Text] [Related]

  • 20. Antitumor activity of paclitaxel (taxol) analogues on MDR-positive human cancer cells.
    Distefano M, Scambia G, Ferlini C, Gallo D, De Vincenzo R, Filippini P, Riva A, Bombardelli E, Mancuso S.
    Anticancer Drug Des; 1998 Jul 15; 13(5):489-99. PubMed ID: 9702212
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.